Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Spahn

Showing results (51-60 of 106) with videos related to

Pageof 11
Sort By:
BJU International|February 22, 2017
Outcome predictors of radical cystectomy in patients with cT4 prostate cancer: a multi-institutional study of 62 patientsMartin Spahn, Alessandro Morlacco, Silvan Boxler, et al.
Medical Physics|September 24, 2017
Assessment of a photon-counting detector for a dual-energy C-arm angiographic systemMoiz Ahmad, Rebecca Fahrig, Leland Pung, et al.
Journal of Cancer Research and Clinical Oncology|June 19, 2014
Methylation of PITX2, HOXD3, RASSF1 and TDRD1 predicts biochemical recurrence in high-risk prostate cancerKirill Litovkin, Steven Joniau, Evelyne Lerut, et al.
Prostate Cancer and Prostatic Diseases|November 14, 2024
Enhancing risk stratification models in localized prostate cancer by novel validated tissue biomarkersCsilla Olah, Fabian Mairinger, Michael Wessolly, et al.
BMC Cancer|December 18, 2019
Preoperative plasma fatty acid metabolites inform risk of prostate cancer progression and may be used for personalized patient stratificationEugenio Zoni, Martina Minoli, Cédric Bovet, et al.
The Journal of Clinical Endocrinology and Metabolism|July 30, 2010
Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centersMartin Fassnacht, Sarah Johanssen, Wiebke Fenske, et al.
The Lancet. Oncology|April 4, 2014
Radiotherapy for renal-cell carcinomaGert De Meerleer, Vincent Khoo, Bernard Escudier, et al.
Biomed Research International|December 13, 2019
miR-221 Augments TRAIL-Mediated Apoptosis in Prostate Cancer Cells by Inducing Endogenous TRAIL Expression and Targeting the Functional Repressors SOCS3 and PIK3R1Markus Krebs, Christoph Behrmann, Charis Kalogirou, et al.
Journal of Clinical Medicine|March 6, 2020
miR-221-3p Regulates VEGFR2 Expression in High-Risk Prostate Cancer and Represents an Escape Mechanism from Sunitinib In VitroMarkus Krebs, Antonio Giovanni Solimando, Charis Kalogirou, et al.
The Journal of Urology|May 15, 2012
Outcome predictors of radical prostatectomy followed by adjuvant androgen deprivation in patients with clinical high risk prostate cancer and pT3 surgical margin positive diseaseMartin Spahn, Alberto Briganti, Umberto Capitanio, et al.
Pageof 11

Showing results (51-60 of 106) with videos related to

Sort By:
Pageof 11
BJU International|February 22, 2017
Outcome predictors of radical cystectomy in patients with cT4 prostate cancer: a multi-institutional study of 62 patientsMartin Spahn, Alessandro Morlacco, Silvan Boxler, et al.
Medical Physics|September 24, 2017
Assessment of a photon-counting detector for a dual-energy C-arm angiographic systemMoiz Ahmad, Rebecca Fahrig, Leland Pung, et al.
Journal of Cancer Research and Clinical Oncology|June 19, 2014
Methylation of PITX2, HOXD3, RASSF1 and TDRD1 predicts biochemical recurrence in high-risk prostate cancerKirill Litovkin, Steven Joniau, Evelyne Lerut, et al.
Prostate Cancer and Prostatic Diseases|November 14, 2024
Enhancing risk stratification models in localized prostate cancer by novel validated tissue biomarkersCsilla Olah, Fabian Mairinger, Michael Wessolly, et al.
BMC Cancer|December 18, 2019
Preoperative plasma fatty acid metabolites inform risk of prostate cancer progression and may be used for personalized patient stratificationEugenio Zoni, Martina Minoli, Cédric Bovet, et al.
The Journal of Clinical Endocrinology and Metabolism|July 30, 2010
Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centersMartin Fassnacht, Sarah Johanssen, Wiebke Fenske, et al.
The Lancet. Oncology|April 4, 2014
Radiotherapy for renal-cell carcinomaGert De Meerleer, Vincent Khoo, Bernard Escudier, et al.
Biomed Research International|December 13, 2019
miR-221 Augments TRAIL-Mediated Apoptosis in Prostate Cancer Cells by Inducing Endogenous TRAIL Expression and Targeting the Functional Repressors SOCS3 and PIK3R1Markus Krebs, Christoph Behrmann, Charis Kalogirou, et al.
Journal of Clinical Medicine|March 6, 2020
miR-221-3p Regulates VEGFR2 Expression in High-Risk Prostate Cancer and Represents an Escape Mechanism from Sunitinib In VitroMarkus Krebs, Antonio Giovanni Solimando, Charis Kalogirou, et al.
The Journal of Urology|May 15, 2012
Outcome predictors of radical prostatectomy followed by adjuvant androgen deprivation in patients with clinical high risk prostate cancer and pT3 surgical margin positive diseaseMartin Spahn, Alberto Briganti, Umberto Capitanio, et al.
Pageof 11